Context Therapeutics Inc (CNTX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.36-0.36%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CNTX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
CNTX — legal / regulatory event — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standar…
Dated 2026-07-31
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On July 29, 2026, Context Therapeutics Inc. (the “Company”) received written notice (the “Notification Letter”) from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”) because the Company’s common stock failed to maintain a minimum…
Why it matters: The earnings date will provide insights into financial health and future plans.
Watch forAn announcement of the next earnings date with a focus on revenue guidance.
Also watch forNo announcement of an earnings date or continued lack of revenue guidance.
Why it matters: The lawsuit's outcome can affect the company's reputation and stock price.
Worry ifA good settlement or dismissal of the stockholder lawsuit.
Less concerning ifA ruling against the company that may lead to financial penalties.
Why it matters: Resolving the Nasdaq compliance issue is crucial. It affects the company's ability to remain listed.
Worry ifThe company resolves the Nasdaq compliance issue and maintains its listing.
Less concerning ifThe company fails to resolve the compliance issue and faces delisting.
Why it matters: If sector growth rebounds, Context Therapeutics could do better in the market.
Supportive ifSector revenue growth shows signs of re-accelerating back toward 10% year over year.
Worry ifSector revenue growth is slowing down and is below current levels.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$338 on $10,000 · ±3.4% | How much price usually moves either way. |
| Bad day | $808 loss on $10,000 · 8.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,924 loss on $10,000 · 89.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Progress on this agreement could boost growth and validate the company's strategy.
Supportive ifA press release about a big milestone or new development in the agreement.
Worry ifNo updates or delays in the agreement's progress.
Why it matters: Interim data will show how well CTIM-76 works for ovarian cancer. Positive results could boost confidence in the drug's potential.
Supportive ifInterim data shows overall response rate above 30% in the Phase 1a trial.
Worry ifInterim data shows overall response rate below 10% in the Phase 1a trial.
Why it matters: Legal problems can impact operations and trust from investors. Clear results matter a lot.
Worry ifA positive outcome or ruling in the ongoing legal challenges.
Less concerning ifMore legal problems or bad rulings that make things worse.
Why it matters: Solving legal problems could improve the company's future. It may also help investors feel better.
Supportive ifA court decision or settlement that helps Context Therapeutics in its ongoing case.
Worry ifMore legal problems or bad rulings in the ongoing case.
Why it matters: The change gives Context full rights to CT-202. This may improve its finances.
Supportive ifContext shares better financial numbers or gains from the BioAtla deal.
Worry ifContext does not use the BioAtla deal well, showing no financial gains.
Why it matters: The start of this trial is key for CT-202's development. It shows progress in Context's pipeline.
Supportive ifCT-202 Phase 1 trial begins in Q3 2026 as planned.
Worry ifTrial initiation is delayed beyond Q3 2026.